 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 November 1997 | Volume 127 Issue 10 | Pages 855-865
Background: Chronic hepatitis C is a major cause of illness and death in the United States. Interferon-
Objective: To estimate the cost-effectiveness of interferon-
Design: Meta-analysis of five prospective trials and cost-effectiveness analysis. Projection of the clinical and economic outcomes expected from loss of hepatitis C virus was done by using a Markov simulation. The potential effect of uncertainty in the model assumptions was tested by using sensitivity analyses.
Data Sources: Search of the MEDLINE database, opinions of expert panels, hospital cost data, and adjusted physician charges.
Patients: Hypothetical cohorts with histologically mild chronic hepatitis C.
Intervention: The model assumed a single 6-month course of recombinant interferon-
Measurements: Life expectancy, quality-adjusted life expectancy, costs, and marginal cost-effectiveness ratios from a managed care perspective.
Results: In 27% of patients with mild chronic hepatitis C treated with interferon-
Conclusions: On the basis of estimations in this mathematical model of the natural history of chronic hepatitis C, treating mild chronic hepatitis with interferon-
Author and Article Information
For author affiliations and current author addresses, see end of text.
ARTICLE
Estimates of the Cost-Effectiveness of a Single Course of Interferon-
2b in Patients with Histologically Mild Chronic Hepatitis C
2b can induce clinical, biochemical, and virologic remission in some patients with chronic hepatitis C, but the long-term cost-effectiveness of this treatment, particularly in patients with histologically mild disease, is unknown. 2b in mild chronic hepatitis C. 2b. 2b for 6 months, serum alanine aminotransferase levels permanently returned to normal and viral status remained negative. The model estimated that interferon-2b treatment in this population should increase life expectancy by 3.1 years if given at 20 years of age, by 1.5 years at 35 years of age, and by 22 days at 70 years of age; discounted marginal cost-effectiveness ratios are $500, $1900, and $62 000 per year of life gained, respectively. Varying the long-term response rates and progression rates for mild and moderate chronic hepatitis to near zero in sensitivity analyses substantially affected the results: Ratios ranged from $31 000 for a 20-year-old patient to $640 000 for a 70-year-old patient. 2b should prolong life expectancy at a reasonable marginal cost per year of life gained, particularly in younger patients.
From the University of Florida College of Medicine, Gainesville, Florida; Baylor College of Medicine, Houston, Texas; Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan; and New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Acknowledgments: The authors acknowledge the contributions of their panel of expert hepatologists (Norman Gitlin, MD, Emory University, Atlanta, Georgia; Karen L. Lindsay, MD, University of Southern California, Los Angeles, California; Dr. Patrick Marcellin and Dr. Castelnau, Hopital Beaujon, Clichy, France; Leonard B. Seeff, MD, Veterans Administration Medical Center, Washington, D.C.; and Eugene R. Schiff, MD, University of Miami, Miami, Florida); the hepatopathologist who reviewed the liver slides for the pooled analysis (Dr. Michele Chevallier, Lyon, France); the principal investigators who represented all of the investigators who allowed us access to their study databases (Drs. Mario Rizzetto and Giorgio Saracco, Torino, Italy; Dr. Thierry Poynard, Paris, France; Dr. J.M. Metreau, Cretiel, France; Karen Lindsay, MD, University of Southern California, Los Angeles, California; and Gary L. Davis, MD, University of Florida, Gainesville, Florida); Haku Ishida, MD, Baylor College of Medicine, Houston, Texas, for statistical assistance; Janice Albrecht, PhD, Schering-Plough Research Institute, Kenilworth, New Jersey, for facilitating access to study databases and histologic material; and Bill Treolar, Clinical Resource Management, Shands Hospital at the University of Florida, Miami, Florida, for assistance with cost data.
Grant Support: In part by Schering-Plough Corp.
Requests for Reprints: Gary L. Davis, MD, PO Box 100214, University of Florida, Gainesville, FL 32610-0214.
Current Author Addresses: Dr. Bennett: Internal Medicine Associates, 104 Doctors Park, Starkville, MS 39759.
Related articles in Annals:
Therapy for Chronic Hepatitis C Therapy for Chronic Hepatitis C: Reducing the UncertaintiesThis article has been cited by other articles:
|
|
 |
|
  D. J. McLernon, J. Dillon, and P. T. Donnan Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review Med Decis Making, July 1, 2008; 28(4): 582 - 592. [Abstract] [PDF]
|
|
|
|
 |
|
 D. W. Hutton, D. Tan, S. K. So, and M. L. Brandeau Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B Ann Intern Med, October 2, 2007; 147(7): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Grieve, J Roberts, M Wright, M Sweeting, D DeAngelis, W Rosenberg, M Bassendine, J Main, and H Thomas Cost effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C Gut, September 1, 2006; 55(9): 1332 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kanwal, I. M. Gralnek, P. Martin, G. S. Dulai, M. Farid, and B. M.R. Spiegel Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis Ann Intern Med, May 17, 2005; 142(10): 821 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Sherman, S. N. Sherman, T. Chenier, and J. Tsevat Health Values of Patients With Chronic Hepatitis C Infection Arch Intern Med, November 22, 2004; 164(21): 2377 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Salomon, M. C Weinstein, and S. J Goldie Taking account of future technology in cost effectiveness analysis BMJ, September 25, 2004; 329(7468): 733 - 736. [Full Text] [PDF]
|
|
|
|
|
|
H Yoshida, R Tateishi, Y Arakawa, M Sata, S Fujiyama, S Nishiguchi, H Ishibashi, G Yamada, O Yokosuka, Y Shiratori, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut, March 1, 2004; 53(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krahn, J. B. Wong, J. Heathcote, L. Scully, and L. Seeff Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 Med Decis Making, January 1, 2004; 24(1): 20 - 29. [Abstract] [PDF]
|
|
|
|
 |
|
 M. G Law, G. J Dore, N. Bath, S. Thompson, N. Crofts, K. Dolan, W. Giles, P. Gow, J. Kaldor, S. Loveday, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001 Int. J. Epidemiol., October 1, 2003; 32(5): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population JAMA, July 9, 2003; 290(2): 228 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Siebert, G Sroczynski, S Rossol, J Wasem, U Ravens-Sieberer, B M Kurth, M P Manns, J G McHutchison, and J B Wong Cost effectiveness of peginterferon {alpha}-2b plus ribavirin versus interferon {alpha}-2b plus ribavirin for initial treatment of chronic hepatitis C Gut, March 1, 2003; 52(3): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Kuehne, U. Bethe, K. Freedberg, and S. J. Goldie Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness Arch Intern Med, December 9, 2002; 162(22): 2545 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Stein, W Rosenberg, and J Wong Cost effectiveness of combination therapy for hepatitis C: a decision analytic model Gut, February 1, 2002; 50(2): 253 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J C L Booth, J O'Grady, and J Neuberger Clinical guidelines on the management of hepatitis C Gut, July 1, 2001; 49(0): I1 - 21. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Singer and K. E. Applegate Cost-Effectiveness Analysis in Radiology Radiology, June 1, 2001; 219(3): 611 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Wong and R. S. Koff Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med, November 7, 2000; 133(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. El-Serag, J. M. Inadomi, and K. V. Kowdley Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis Ann Intern Med, February 15, 2000; 132(4): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Pawlotsky, G. Germanidis, P.-O. Frainais, M. Bouvier, A. Soulier, M. Pellerin, and D. Dhumeaux Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy J. Virol., August 1, 1999; 73(8): 6490 - 6499. [Abstract] [Full Text]
|
|
|
|
|
|
E. Henley, D. J. van Leeuwen, J. B. Wong, R. S. Koff, and S. G. Pauker Cost-effectiveness of Interferon Treatment for Hepatitis C JAMA, June 9, 1999; 281(22): 2083 - 2084. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Wong, W. G. Bennett, R. S. Koff, and S. G. Pauker Pretreatment Evaluation of Chronic Hepatitis C: Risks, Benefits, and Costs JAMA, December 23, 1998; 280(24): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bowman and D. E. Nicklin New Developments in Family Medicine JAMA, May 13, 1998; 279(18): 1437 - 1438. [Full Text] [PDF]
|
|
|
|
 |
|
 INTERFERON-ALPHA FOR HEPATITIS C: IS IT WORTH IT? Journal Watch (General), December 12, 1997; 1997(1212): 1 - 1. [Full Text]
|
|
Article
